Method of producing a differentiated mammalian cell comprising culturing a single mammalian blastomere

• US 10,584,313 B2
• Filed: 07/23/2014
• Issued: 03/10/2020
• Est. Priority Date: 02/23/2007
• Status: Active Grant

• Current Assignee: Astellas Institute for Regenerative Medicine (Astellas Pharma Incorporated)
• Original Assignee: Astellas Institute for Regenerative Medicine (Astellas Pharma Incorporated)
• Inventors: Lanza, Robert P., Chung, Young Gie
• Primary Examiner(s): Moloye, Titilayo
• Application Number:
  US14/338,596
• Publication Number:
  US 20150175960A1
• Time in Patent Office: 2,057 Days
• CPC Class Codes: A01K 2227/105 Murine
• CPC Class Codes: A01K 2267/0393 Animal model comprising a reporter system for screening tests
• CPC Class Codes: A01K 67/0273 Cloned vertebrates
• CPC Class Codes: A01K 67/0275 Genetically modified vertebrates, e.g. transgenic
• CPC Class Codes: A61P 1/04 for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
• CPC Class Codes: A61P 1/16 for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• CPC Class Codes: A61P 13/00 Drugs for disorders of the urinary system
• CPC Class Codes: A61P 13/12 of the kidneys
• CPC Class Codes: A61P 17/02 for treating wounds, ulcers, burns, scars, keloids, or the like
• CPC Class Codes: A61P 19/08 for bone diseases, e.g. rachitism, Paget's disease
• CPC Class Codes: A61P 21/02 Muscle relaxants, e.g. for tetanus or cramps
• CPC Class Codes: A61P 21/04 for myasthenia gravis
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system
• CPC Class Codes: A61P 25/16 Anti-Parkinson drugs
• CPC Class Codes: A61P 25/28 for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• CPC Class Codes: A61P 3/06 Antihyperlipidemics
• CPC Class Codes: A61P 3/10 for hyperglycaemia, e.g. antidiabetics
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 35/02 specific for leukemia
• CPC Class Codes: A61P 37/04 Immunostimulants
• CPC Class Codes: A61P 9/00 : Drugs for disorders of the cardiovascular system
• CPC Class Codes: C07K 14/43595 : from coelenteratae, e.g. medusae
• CPC Class Codes: C12N 2501/235 : Leukemia inhibitory factor [LIF]
• CPC Class Codes: C12N 2501/998 : Proteins not provided for elsewhere
• CPC Class Codes: C12N 2502/02 : embryonic cells
• CPC Class Codes: C12N 2506/02 : from embryonic cells
• CPC Class Codes: C12N 2517/04 : Cells produced using nuclear transfer
• CPC Class Codes: C12N 2533/52 : Fibronectin; Laminin
• CPC Class Codes: C12N 5/0603 : Embryonic cells production of embryos, nuclear transfer A01K67/027; Embryoid bodies
• CPC Class Codes: C12N 5/0604 : Whole embryos; Culture medium therefor
• CPC Class Codes: C12N 5/0606 : Pluripotent embryonic cells, e.g. embryonic stem cells [ES] embryonic germ cells C12N5/0611, induced pluripotent stem cells C12N5/0696
• CPC Class Codes: C12N 5/0619 : Neurons
• CPC Class Codes: C12N 5/0621 : Eye cells, e.g. cornea, iris pigmented cells photoreceptors C12N5/062
• CPC Class Codes: C12N 5/0634 : Cells from the blood or the immune system
• CPC Class Codes: C12N 5/0657 : Cardiomyocytes; Heart cells

Abstract

The present invention relates generally to the field of somatic cell nuclear transfer (SCNT) and to the creation of cloned animals and cells. The disclosure relates to a method of cloning a mammal, obtaining pluripotent cells such as embryonic stem cells, or for reprogramming a mammalian cell using an oocyte and a fertilized embryo.

Claims

1. A method of producing a differentiated mammalian cell, the method comprising

culturing a single mammalian blastomere obtained from a mammalian embryo in the presence of blastocyst medium and about 5-10 μ

g/ml laminin, and in the absence of previously-derived pluripotent stem cells, until embryonic stem (ES) cells are produced, and

culturing the ES cells under conditions that induce their differentiation into a desired differentiated cell.

2. The method of claim 1, wherein the blastomere is a human blastomere.

3. The method of claim 1, wherein the differentiated mammalian cell is a mesodermal cell.

4. The method of claim 1, wherein the differentiated mammalian cell is an endodermal cell.

5. The method of claim 1, wherein the differentiated mammalian cell is an ectodermal cell.

6. The method of claim 1, wherein the differentiated mammalian cell is a retinal pigmented epithelial (RPE) cell, a hematopoietic cell, a red blood cell, a platelet, a pancreatic beta cell, a skin cell, a cardiomyocyte, a smooth muscle cell, an endothelial cell, a hepatocyte, a neuron, a glia cell, a skeletal muscle cell, or a vascular cell.

7. The method of claim 1, wherein the differentiated mammalian cell is an RPE cell.